Evidence map›Paper›PMID 28533223›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR

Maura N Dickler, Sara M Tolaney, Hope S Rugo, Javier Cortés, Véronique Diéras, Debra Patt, Hans Wildiers, Clifford A Hudis, Joyce O'Shaughnessy, Esther Zamora and 4 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02102490 (A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer), which is not on this map. Cited by 382 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
382citing papers in PubMed, 9 pooled it
50.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02102490 phase2completednot on this map

A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

TypeinterventionalSponsorEli Lilly and CompanyRan2014 to 2018Enrolled132ConditionsMetastatic Breast CancerArmsAbemaciclib
3 · Its place in the literature

Who cites it

382 citing papers in PubMed, 9 syntheses or guidelines pooled it, 671 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review

322 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Maura N DicklerMemorial Sloan Kettering Cancer Center, New York, New York. dicklerm@mskcc.org.
Sara M TolaneyDana-Farber Cancer Institute, Boston, Massachusetts.
Hope S RugoUniversity of California San Francisco Comprehensive Cancer Center, San Francisco, California.
Javier CortésVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Véronique DiérasInstitut Curie, Paris, France.
Debra PattTexas Oncology, Austin, Texas.
Hans WildiersDepartment of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
Clifford A HudisMemorial Sloan Kettering Cancer Center, New York, New York.
Joyce O'ShaughnessyBaylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas.
Esther ZamoraVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Denise A YardleySarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, Tennessee.
Martin FrenzelEli Lilly and Company, Indianapolis, Indiana.
Andrew KoustenisEli Lilly and Company, Indianapolis, Indiana.
José BaselgaMemorial Sloan Kettering Cancer Center, New York, New York.
Kettering University · USVall d'Hebron Institute of OncologyDana-Farber Cancer Institute · USInstitut Curie · FRMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAminopyridinesBenzimidazolesBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisabemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID28533223
PMCPMC5581697
OpenAlexW2617437931

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.